| Similar Articles |
|---|
 |
The Motley Fool
June 14, 2010
Bruce Bigelow |
Genetic Testing Companies in San Diego, Boston, and San Francisco Studying FDA Letters The letters notify the companies that genome-sequencing tests they offer to consumers are medical devices that require the agency's approval.   |
The Motley Fool
May 28, 2010
Brian Orelli |
Is It Time to Make Money Investing in Genetic Testing? Easier said than done. |
Chemistry World
January 8, 2013
Andrew Turley |
Illumina investment push Gene sequencing company Illumina has struck a $450 million deal to buy privately owned US firm Verinata Health, which specializes in non-invasive tests for early identification of fetal chromosomal abnormalities. |
Bio-IT World
June 17, 2004
Michael A. Goldman |
A Hip Approach to Gene Hunting IntegraGen defines the genetic blueprint of complex human diseases and delivers validated disease markers and therapeutic targets for a better diagnosis and a causal treatment of common diseases, based on its unique genomic analysis expertise. |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response. |
Bio-IT World
May 2006
Kevin Davies |
Decoding the Genetics of Common Disease Icelandic biopharma deCODE Genetics' Kari Stefansson says his company's search for genes underlying common diseases is not only pushing promising new drug candidates into the clinic but also revealing new insights into the very basis of common disease. |
Chemistry World
August 22, 2014
Phillip Broadwith |
Illumina targets cancer diagnostics Genetic sequencing heavyweight Illumina has partnered with three major pharmaceutical firms in a bid to develop a universal sequencing-based oncology test system. |
The Motley Fool
October 24, 2007
Brian Orelli |
Illumina's Illuminating Results There was stellar revenue growth, but margins and stock compensations pulled the bottom line down. |
Bio-IT World
August 15, 2005
Kevin Davies |
TGen's Discovery Pipeline in the Desert At the Translational Genomics Research Institute, researchers have developed an industrial-style informatics strategy and discovery infrastructure that has pinpointed some 25 disease genes in the past 24 months, many of which are pending identification. |
Chemistry World
January 27, 2012
Sarah Houlton |
Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach. |
The Motley Fool
January 14, 2010
Brian Orelli |
$1,000 Genomes, Here We Come Illumina jumps on news of its $10,000 genome. |
Managed Care
August 2004
Thomas Morrow |
10,000 Cells on a Chip Signal Start of New Era of Diagnosis Diseases will soon be defined by biochemical pathways and genetic interactions. Biochips may identify patients likely to respond to therapeutic agents. All of this is a big deal for health plans. |
Fast Company
Christina Farr |
Bill Gates, Illumina To Fund $100M Blood Test For Cancer Bill Gates, Jeff Bezos's venture fund Bezos Expeditions, and Arch Venture Partners will also contribute to the venture. Grail will be based in San Francisco, and Illumina will retain majority control. |
The Motley Fool
August 6, 2008
Brian Orelli |
Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out. |
BusinessWeek
February 20, 2006
Gene G. Marcial |
Fast Growth At Illumina Is In The Genes The company has become a rising star in the complex analysis of gene variation, and the stock shows it. |
Fast Company
November 2009
David H. Freedman |
The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens. |
The Motley Fool
July 25, 2007
Brian Orelli |
Shiny Happy Illumina Illumina, which makes chips that can distinguish one million different genes, announced another stellar quarter. That makes eight in a row. |
Fast Company
September 2000
John Ellis |
The Secret of Life The mapping of the human genome, says Craig Venter, will change science, research, medicine, politics, health insurance, and the way biology looks at the last 3 billion years of evolution. And that's just the beginning. |
The Motley Fool
August 27, 2004
W.D. Crotty |
deCODE This deCODE genetics' auditor's resignation provides a buying opportunity for those who buy story stocks. |
Managed Care
May 2001
Michael D. Dalzell |
Powerful Opportunities For Good and Greed Genetic advances could spawn incredible improvements in health care. Given public demand, they also pose what may be unmanageable issues of resource use... |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
Bio-IT World
February 2006
Kevin Davies |
The Cancer Genome Atlas Pilot Launches Researchers from the National Cancer Institute and the National Human Genome Research Institute announced the launch of a three-year, $100 million pilot program for the Human Cancer Genome Project. |
Wired
November 17, 2007
Thomas Goetz |
23AndMe Will Decode Your DNA for $1,000. Welcome to the Age of Genomics A much-anticipated Silicon Valley startup called 23andMe offers a thorough tour of your genealogy, tracing your DNA back through the eons. |
The Motley Fool
August 12, 2009
Brian Orelli |
The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing. |
IEEE Spectrum
March 2013
Eliza Strickland |
The Gene Machine and Me Ion Torrent's chip-based genome sequencer is cheap, fast, and poised to revolutionize medicine |
BusinessWeek
May 9, 2005 |
A Genome Pioneer Looks Forward Dr. Francis Collins discusses the end of the Human Genome Project and says an "outpouring of discoveries" is coming soon. |
The Motley Fool
April 27, 2007
Brian Orelli |
Making Money Off Your Competitors Affymetrix is looking appealing with a few new products and potential revenues from an unlikely source. Investors, take note. |
IEEE Spectrum
February 2010
Mark Anderson |
Genome as Commodity In a few years, millions will have purchased their own genome. The cultural ramifications of a $100 genome are as wide and deep as those of any other recent innovation, including search engines and cellphones. |
Bio-IT World
Jul/Aug 2006
Deb Janssen |
Managing the Microarray Data Mountain Genomic studies often involve thousands of samples and require hundreds of thousands of assays per sample. Microarray manufacturers are scurrying to satisfy researcher demands for increased array density, sample number, and content flexibility. |
Wired
April 21, 2008
Rachel Swaby |
Chromosome, Proteome ... Decoding the DNA of '-omes' The genome alone can't explain how our bodies work. We need to decode a lot of other complex biological systems that regulate how we develop. |
CIO
July 15, 2001
Stephanie Overby |
Iceland's Dilemma: Privacy vs. Progress A small Icelandic startup has been granted a 12-year license to create and manage a database of the entire nation's medical and genetic records. Can it make medical history without violating patient privacy? |
Popular Mechanics
November 12, 2009
Bijal P. Trivedi |
5 Animal Genomes That May Hold Cures to Human Diseases Having the genomic information will guide pharmaceutical assessments and new experimental gene therapies, many of which are being done in animals. |
The Motley Fool
July 22, 2009
Brian Orelli |
Levering the Genome Lower revenue can't stop Illumina from turning in a good bottom line. |
Bio-IT World
September 2005
Mark D. Uehling |
Kings of Genes and Data The speed by which things move at Iceland's deCODE supports the company's claim that it is not only reconnecting the bifurcated worlds of drug discovery and clinical research - it is also internally cross-pollinating ideas between those two realms. |
HHMI Bulletin
February 2011 |
Crucibles of Dynamism Puzzling pockets of redundancy account for about 5 percent of the human genome. Investigator Evan Eichler found a way to interpret what is happening in these areas of genetic repetition. |
Bio-IT World
August 13, 2003
Michael Greeley |
Two Cents on the '$1,000 Genome' Are venture capitalists still looking for 'the killer app'? Funding the next big idea won't be so easy. Affordable, individualized genome sequencing holds great promise, but making the claims sound too grandiose can be dangerous. |
BusinessWeek
June 13, 2005
John Carey |
The NIH's Roadmap for Research Charting the human genome was just the beginning. Now the focus is creating pathways that will lead to practical applications. |
